Researchers find evidence of survival gains in bone marrow disease

Dec 14, 2009

A recent study, published in the December issue of Mayo Clinic Proceedings, demonstrates new survival data for the blood disorder myelofibrosis. This retrospective study is the largest ever conducted in young patients with primary myelofibrosis.

Myelofibrosis is a serious disorder that disrupts the body's normal production of blood cells. The result is extensive scarring in the bone marrow, leading to severe anemia, weakness, fatigue and often, an enlarged spleen and liver.

"In the past 20 years, management of primary myelofibrosis has incorporated new treatment approaches, but survival benefits for have not been confirmed," says Ayalew Tefferi, M.D., senior author of the study and a Mayo Clinic hematologist. "Our study reviewed almost 30 years of data on myelofibrosis to obtain mature survival data in the particular patient population."

Study findings suggest that high- to intermediate-risk patients in whom the diagnosis of primary myelofibrosis was made after 1986 lived longer than those whose diagnosis was made earlier. The improvement in survival was most impressive for patients whose diagnosis was made in the most recent decade (ie, 1996-2005) in which median survival was not reached.

"Such retrospective studies cannot accurately identify the reasons for improved survival but alert clinical investigators to avoid using historical controls to determine the value of new treatment modalities such as allogeneic hematopoietic cell transplantation," says Dr. Tefferi.

"These observations are encouraging and suggest a beneficial effect from modern therapeutic approaches in myelofibrosis. The current findings are based on retrospective observation and need to be validated in properly designed prospective studies."

Source: Mayo Clinic (news : web)

Explore further: Adult survivors of childhood eye cancer experience few cognitive or social setbacks

add to favorites email to friend print save as pdf

Related Stories

Multiple myeloma clinical trial closes early

Apr 05, 2007

Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose ...

How less can be more when treating some kidney cancers

Jan 09, 2008

A new Mayo Clinic study suggests that removing the entire kidney from younger patients with small kidney tumors may lead to decreased overall survival compared with an operation that removes the tumor but leaves the kidney ...

Recommended for you

Marker polyps do not cause cancer

4 hours ago

Although serrated polyps usually are associated with colorectal cancer, it turns out that such polyps are themselves not dangerous, according to a Norwegian study released this week in BMJ Gut.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.